Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cipla
Teva
Boehringer Ingelheim
Colorcon
Deloitte
Daiichi Sankyo
Harvard Business School
Healthtrust

Generated: August 20, 2018

DrugPatentWatch Database Preview

DEPAKOTE ER Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Depakote Er patents expire, and when can generic versions of Depakote Er launch?

Depakote Er is a drug marketed by Abbvie and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-seven countries.

The generic ingredient in DEPAKOTE ER is divalproex sodium. There are seventeen drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.

Drug patent expirations by year for DEPAKOTE ER
Synonyms for DEPAKOTE ER
133299-66-8
644VL95AO6
76584-70-8
99-66-1 (Parent)
A838751
AB01568255_01
AB2000231
Abbott 50711
Abbott-50711
AC1Q1V4Q
AC1Q1VPW
AKOS015895200
AN-6581
API0002433
AS-17254
C-19234
C16H31NaO4
CC-27204
CHEBI:4667
CHEMBL2105613
D00304
D03LGY
Delepsine
Depacon (TN)
Depakote
Depakote (TN)
Depakote CP
Depakote ER (TN)
Depakote Sprinkle
Depakote;Epival
Divalproate
divalproex
DIVALPROEX SODIUM
Divalproex sodium (USP)
Divalproex sodium [USAN:USP]
Divalproex sodium [USAN]
Divalproex sodium salt
Divalproex sodium, Depakote, Epival
Divalproexsodium
DTXSID70227388
Epilex
Epival
Epival (TN)
Ergenyl Chrono (TN)
FT-0625375
HMS3651C17
I06-0339
LS-101863
MolPort-006-167-562
MSRILKIQRXUYCT-UHFFFAOYSA-M
Natrium hydrogen bis(2-propylvalerat)
OR339103
Pentanoic acid, 2-propyl-, sodium salt (2:1)
pentanoic acid, 2-propyl-, sodium salt(2:1)
potassium valproic acid dipropylacetate
s1703
SCHEMBL40996
Semisodium Valproate
Sodium 2-propylpentanoate 2-propylpentanoic acid
sodium 2-propylpentanoate--2-propylpentanoic acid (1:1)
Sodium 2-propylpentanoate-2-propylpentanoic acid (1:1)
Sodium divalproate
Sodium hydrogen bis(2-propylpentanoate)
Sodium hydrogen bis(2-propylvalerate)
Sodium hydrogen bis(2-propylvalerate), oligomer
Sodium hydrogen divalproate
sodium valproic acid valproate
sodium; 2-propylpentanoate; 2-propylpentanoic acid
Sprinkle
U058
UNII-644VL95AO6
Valance (TN)
Valcote
Valdisoval
Valparin
Valproate semisodique
Valproate semisodique [French]
Valproate semisodium
Valproate semisodium (INN)
Valproate semisodium [INN]
Valproato semisodico
Valproato semisodico [Spanish]
Valproatum seminatricum
Valproatum seminatricum [Latin]
Valproic acid semisodium salt (2:1)
Zalkote. (TN)

US Patents and Regulatory Information for DEPAKOTE ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for DEPAKOTE ER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-001 Aug 4, 2000 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 ➤ Sign Up ➤ Sign Up
Abbvie DEPAKOTE ER divalproex sodium TABLET, EXTENDED RELEASE;ORAL 021168-002 May 31, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for DEPAKOTE ER
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe ➤ Sign Up

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
US Army
Argus Health
Julphar
Federal Trade Commission
Moodys
Citi
Fuji
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.